U
080720
vs
K
KOSPI 200
Over the past 12 months, Union Korea Pharm Co Ltd has underperformed KOSPI 200, delivering a return of 0% compared to KOSPI 200's +152% growth.
Stocks Performance
080720 vs KOSPI 200
Performance Gap
080720 vs KOSPI 200
Performance By Year
080720 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Union Korea Pharm Co Ltd
Glance View
Union Korea Pharm Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Wonju, Gangwon-Do. The company went IPO on 2018-07-26. is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The firm manufactures and sells specialty medicines through formulations such as solid dosage forms, liquid injections, and cefa powder injections. Major products include antibiotics such as kepodon injection and ceftazime injection 1g for the prevention and treatment of infectious diseases; musculoskeletal drugs for treating arthritis contains unihyal injection and galithio injection; circulatory system dugs for the treatment of cerebrovascular diseases, such as cacetile tab and limasta tab; as well as drugs for digestive system such as digestive disorders. In addition, the Company engaged in the contract manufacturing operation (CMO) business for other pharmaceutical companies. The firm distributes its products within domestic market and to overseas markets including Middle East, Southeast Asia and Latin America.
